Core-glycosylated HCV envelope proteins

Details Core-glycosylated HCV envelope proteins Core-glycosylated HCV envelope proteins

2007-07-03

2007-07-03

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S185100, C424S189100, C424S193100, C424S093100, C435S069100, C435S069900, C435S069700, C435S070100

Reexamination Certificate

active

10128590

ABSTRACT:
The current invention relates to HCV envelope proteins or parts thereof which are the product of expression in eukaryotic cells. More particularly said HCV envelope proteins are characterized in that on average up to 80% of their N-glycosylation sites are core-glycosylated. Of these N-glycosylated sites more than 70% are glycosylated with an oligomannose having a structure defined by Man(8 to 10)-GlcNAc(2). Furthermore, the ratio of the oligomannose with structure Man(7)-GlcNAc(2) over the oligomannose with structure Man(8)-GlcNAc(2) is less than or equal to 0.45. Less than 10% of the oligomannoses is terminated with an α1,3 linked mannose. The HCV envelope proteins of the invention are particularly suited for diagnostic, prophylactic and therapeutic purposes. A suitable eukaryotic cell for production of the HCV envelope proteins of the invention is aHansenulacell.

REFERENCES:
patent: 4395395 (1983-07-01), Tabor et al.
patent: 5135854 (1992-08-01), MacKay et al.
patent: 5350671 (1994-09-01), Houghton et al.
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5698390 (1997-12-01), Houghton et al.
patent: 5712087 (1998-01-01), Houghton et al.
patent: 5747239 (1998-05-01), Wang et al.
patent: 6150134 (2000-11-01), Maertens et al.
patent: 6245503 (2001-06-01), Maertens et al.
patent: 6613333 (2003-09-01), Leroux-Roels et al.
patent: 6855318 (2005-02-01), Maertens et al.
patent: 6890737 (2005-05-01), Maertens et al.
patent: 7048930 (2006-05-01), Bosman et al.
patent: 2004/0151735 (2004-08-01), Maertens et al.
patent: 2006/0078932 (2006-04-01), Maertens et al.
patent: 0 468 527 (1992-01-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 94/01132 (1994-01-01), None
patent: WO 95/12677 (1995-05-01), None
patent: 96/04385 (1996-02-01), None
patent: WO 99/24466 (1999-05-01), None
patent: 99/54735 (1999-10-01), None
patent: 99/67285 (1999-12-01), None
patent: WO 02/055548 (2002-07-01), None
patent: WO 03/051912 (2003-06-01), None
Liang et al. Annual of internal Medicine 2000, vol. 132, No. 4, pp. 296-305.
Frasca et al. J. Immunol. 1999, vol. 163, pp. 650-658.
Faic et al. Science 2000, vol. 289, 2003a-2004.
Sarobe et al. J. Virol. 2003. vol. 77, No. 20.
Rosa et al. Proc. Natl. Acad. Sci. 1996, vol. 93, pp. 1759-1763.
Ralston et al. J. Virol. 1993, vol. 67, No. 11, pp. 6753-6761.
Lechmann et al. Hepatology 1996, vol. 24(4), pp. 790-795.
Fournilier et al. J. Virol. 2001,vol. 75, No. 24, pp. 12088-12097.
Dubuisson et al. J. B. C. 2000, vol. 275, No. 39, pp. 30605-30609.
Meunier et al. J. Gene. Virol. 1999, vol. 80, pp. 887-896.
Inudoh et al. Vaccine 1996, vol. 14, No. 17/18, pp. 1590-1596.
Fournillier-Jacob et al. J. Gene. Virol. 1996, vol. 77, pp. 1055-1064.
Kuroda et al., “Heptitis B Virus Envelope L Protein Particles”, The Journal of Biological Chemistry, vol. 267, No. 3, Issue of Jan. 25, pp. 1953-1961, 1992.
Kuroda et al., “Saccharomyces cerevisiaecan release hepatitis B virus surface antigen (HbsAg) particles into the medium by its secretory apparatus”, Applied Microbiology Biotechnology (1993) 40:333-340.
Helenius, “How N-linked Oligosaccharides Affect Glycoprotein Folding in the Endoplasmic Reticulum”, Molecular Biology of the Cell, vol. 5, 253-265, Mar. 1994.
Ghany et al, Hepatology, 2003, vol. 38, No. 5, pp. 1092-1094.
Choo et al, PNAS, Vaccination of Chimpanzees Against Infection by the Hepatitis C Virus, 1994, pp. 1294-1298.
Houghton et al, Prospects for Prophylactic and Therapeutic Hepatitis C Virus Vaccines, 1995, pp. 237-243.
Houghton et al, Viral Hepatitis and Liver Disease, 1997, Apr. 21-25, 1996, pp. 656-659.
Leroux-Roels et al, Hepatology, 2003, 34, 449A.
Nevens et al, Hepatology, A Pilot Study of Therapeutic Vaccination With Envelope Protein E1 in 35 Patients With Chronic Hepatitis C, 2003, 38, pp. 1289-1296.
Pawlotsky, Hepatology, Hepatitis C. Development of New Drugs and Clinical Trials: Promises and Pitfalls, 2003, 39, pp. 554-567.
Forns et al, J. Hepatol, The Challenge of Developing a Vaccine Against Hepatitis C Virus, 2002, 37, pp. 684-695.
Major et al, J. Virology, Previously Infected and Recovered Chimpanzees Exhibit Rapid Responses . . . upon Rechallenge, 2002, 76, pp. 6586-6595.
Bassett et al, Hepatology, Protective Immune Response to Hepatitis C Virus . . . Infection, 2001, 33, pp. 1479-1487.
Weiner et al, J. Virology, Intrahepatic Genetic Inoculation of Hepatitis C Virus . . . Immunity, 2001, 75, pp. 7142-7148.
Mehta et al, Lancet, Protection Agaist Persistence of Hepatitis C, 2002, 359, pp. 1478-1483.
Herscovics, FASEB, Glycoprotein Biosynthesis in Yeast, 1993, 7, pp. 540-550.
Botarelli et al, Gastroenterology, T-Lymphocyte Response to Hepatitis C Virus in Different Clinical Courses of Infection, 1993, 104, pp. 580-587.
Pages 36-38 of WO2004/041853 (2004).
Pages 58-59 of WO02/055548 (2002).
Grogan et al. Annu Rev. Biochem 2002, 71; 593-634.
Bertozzi et al, Chemical Glycobiology,Science, vol. 291, Mar. 23, 2001, 2357-2364.
Innogenetics web site print out (URL: innogenetics.be) (2004).
Diminsky et al, Vaccine, 1997, vol. 15, No. 6/7, pp. 637-647.
Mustilli et al, Res. Microbiol. 1999, vol. 150, pp. 179-187.
Gellissen G, Janowicz ZA, Weydemann U, Melber K, Strasser AW, Hollenberg CP. High-level expression of foreign genes in Hansenula polymorpha. Biotechnol Adv. 1992;10(2):179-89.

Affiliated with

Also associated with

Rating

Core-glycosylated HCV envelope proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Core-glycosylated HCV envelope proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Core-glycosylated HCV envelope proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3739998